

Catherine Thieblemont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7152991/publications.pdf>

Version: 2024-02-01

338
papers

19,654
citations

11608

70
h-index

13338

130
g-index

345
all docs

345
docs citations

345
times ranked

14576
citing authors

#	ARTICLE	IF	CITATIONS
1	A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. <i>Journal of Nuclear Medicine</i> , 2022, 63, 172-179.	2.8	96
2	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
3	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	0.8	90
4	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	15.2	182
5	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1058-1069.	0.6	3
6	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	13.9	278
7	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts. <i>HemaSphere</i> , 2022, 6, e680.	1.2	0
8	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 431-439.	1.3	26
9	The Alternative RelB NF- κ B Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells. <i>Biomedicines</i> , 2022, 10, 348.	1.4	5
10	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. <i>Diagnostics</i> , 2022, 12, 417.	1.3	9
11	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. <i>Bone Marrow Transplantation</i> , 2022, 57, 627-632.	1.3	4
12	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	1.7	2
13	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	13.9	243
14	Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma. <i>Haematologica</i> , 2022, , .	1.7	0
15	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials. <i>Leukemia and Lymphoma</i> , 2022, 63, 1544-1555.	0.6	3
16	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. <i>Cancers</i> , 2022, 14, 1761.	1.7	0
17	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	15.2	114
18	Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method. <i>Hematological Oncology</i> , 2022, 40, 1086-1089.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Comparing apples and oranges: The ZUMA, TRANSFORM and BELINDA trials. <i>Hematological Oncology</i> , 2022, 40, 1090-1093.	0.8	7
20	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	1.3	12
21	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2063-2073.	0.6	9
22	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
23	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	1.0	4
24	Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Neurology</i> , 2022, 99, 511-515.	1.5	9
25	Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors. <i>Haematologica</i> , 2021, 106, 593-596.	1.7	1
26	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. <i>Haematologica</i> , 2021, 106, 859-862.	1.7	12
27	Deep-Learning ¹⁸ F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 30-36.	2.8	75
28	Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. <i>Journal of Dermatology</i> , 2021, 48, e49-e71.	0.6	14
29	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
30	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 827-839.	0.6	13
31	Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. <i>Annals of Hematology</i> , 2021, 100, 979-986.	0.8	9
32	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a005934.	0.5	1
33	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	1.2	8
34	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1700-1709.	1.3	6
35	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021, 39, 1203-1213.	0.8	39
36	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021, 17, 1295-1310.	1.1	6
38	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/CD56 ⁺ lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Transplantation Cellulaire (SFGM-TC). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	2.0	5
39	CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL. <i>Journal of Clinical Oncology</i> , 2021, 39, 7543-7543.	0.8	3
40	CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma. <i>Human Pathology</i> , 2021, 111, 84-91.	1.1	1
41	Aspects biologiques et th�rapeutiques des lymphomes de la zone marginale. <i>Revue Francophone Des Laboratoires</i> , 2021, 2021, 56-63.	0.0	0
42	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA. <i>Journal of Clinical Oncology</i> , 2021, 39, 7544-7544.	0.8	3
43	Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 7508-7508.	0.8	10
44	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. <i>Cancer Medicine</i> , 2021, 10, 5101-5109.	1.3	4
45	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. <i>American Journal of Hematology</i> , 2021, 96, E311-E314.	2.0	7
46	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 111.	6.9	11
47	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	1.2	88
48	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	5
49	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. <i>Cancers</i> , 2021, 13, 3998.	1.7	12
50	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	2.5	8
51	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	3.2	42
52	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216.	0.4	14
53	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 388-398.	1.2	47
54	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	2.2	27
56	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 1403-1415.	5.1	222
57	Splenic Marginal Zone Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 127-142.	0.2	0
58	Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2021, , .	2.0	1
59	Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1453-1465.	0.8	3
60	Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 1433-1433.	0.6	8
61	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 739-739.	0.6	12
62	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. <i>Blood</i> , 2021, 138, 885-885.	0.6	5
63	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	0.6	3
64	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	0.6	8
65	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021, 138, 2832-2832.	0.6	4
66	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. <i>Blood</i> , 2021, 138, 3495-3495.	0.6	0
67	A Systematic Review and a Survey Both Reveal Wide Heterogeneity across Trials and Investigators on Time-to-Event Endpoints Definitions in Marginal Zone Lymphoma. <i>Blood</i> , 2021, 138, 4502-4502.	0.6	0
68	Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study. <i>Blood</i> , 2021, 138, 3533-3533.	0.6	2
69	A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry. <i>Blood</i> , 2021, 138, 92-92.	0.6	7
70	Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study. <i>Blood</i> , 2021, 138, 1411-1411.	0.6	2
71	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2021, 138, 306-306.	0.6	5
72	Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. <i>Blood</i> , 2021, 138, 91-91.	0.6	70

#	ARTICLE	IF	CITATIONS
73	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene CiloleuceL (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021, 138, 430-430.	0.6	9
74	TisagenlecleuceL Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021, 138, LBA-6-LBA-6.	0.6	9
75	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
76	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 613-622.	1.3	15
77	Specific renal infiltration by aggressive lymphoma mimicking tumor lysis syndrome. <i>Intensive Care Medicine</i> , 2020, 46, 123-124.	3.9	0
78	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	1.2	15
79	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020, 105, e33-e36.	1.7	31
80	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 17-29.	0.6	197
81	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , 2020, 80, 219-224.	1.7	8
82	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	0.8	73
83	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide+rituximab (R2) vs. rituximab+placebo in relapsed/refractory indolent non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2020, 111, 409-416.	0.7	6
84	Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. <i>Lancet Haematology</i> , 2020, 7, e798-e807.	2.2	12
85	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 5607-5615.	2.5	222
86	NF- κ B in the New Era of Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 677-687.	3.8	49
87	G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2347-2349.	1.3	40
88	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2371-2381.	1.9	3
89	Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort. <i>British Journal of Haematology</i> , 2020, 191, e90-e94.	1.2	3
90	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	1.1	26

#	ARTICLE	IF	CITATIONS
91	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	2.5	67
92	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <sc>LYSA</sc> group. <i>Hematological Oncology</i> , 2020, 38, 446-455.	0.8	5
93	Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study. <i>Annals of Hematology</i> , 2020, 99, 1615-1625.	0.8	10
94	Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. <i>Blood Cancer Journal</i> , 2020, 10, 62.	2.8	32
95	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e511-e522.	2.2	201
96	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	6.9	17
97	Earlier Steroid Use with Axicabtagene Ciloleucef (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101.	2.0	13
98	Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. <i>PharmacoEconomics - Open</i> , 2020, 4, 575-591.	0.9	4
99	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. <i>Annals of Hematology</i> , 2020, 99, 1771-1778.	0.8	8
100	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	1.7	29
101	Stabilization of β -catenin upon B-cell receptor signaling promotes NF- κ B target genes transcription in mantle cell lymphoma. <i>Oncogene</i> , 2020, 39, 2934-2947.	2.6	15
102	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. <i>Leukemia and Lymphoma</i> , 2020, 61, 887-895.	0.6	3
103	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	0.6	119
104	Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. <i>Targeted Oncology</i> , 2020, 15, 249-259.	1.7	108
105	Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. <i>Blood</i> , 2020, 136, 28-30.	0.6	13
106	Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. <i>Blood</i> , 2020, 136, 42-42.	0.6	0
107	A Retrospective Study of 67 Inflammatory Waldenström's Macroglobulinemia. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
108	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	2.2	64

#	ARTICLE	IF	CITATIONS
109	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 115.	1.0	13
110	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S248-S249.	0.2	1
111	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	0.8	195
112	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1561-1572.	2.0	6
113	Hairy Cell Leukemia: Results of the French Retrospective Cohort After 10 Years of Follow Up. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S313-S314.	0.2	0
114	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL). <i>International Journal of Hematology</i> , 2019, 110, 11-19.	0.7	7
115	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019, 125, 2291-2299.	2.0	14
116	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	0.8	277
117	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	0.8	388
118	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019, 29, 1243-1257.e10.	7.2	56
119	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 244-245.	0.8	3
120	The Need for a Consensus Next-Generation Sequencing Panel for Mature Lymphoid Malignancies. <i>HemaSphere</i> , 2019, 3, e169.	1.2	26
121	Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. <i>Annals of Hematology</i> , 2019, 98, 195-203.	0.8	5
122	Burden of illness of follicular lymphoma and marginal zone lymphoma. <i>Annals of Hematology</i> , 2019, 98, 175-183.	0.8	18
123	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2019, 134, 347-347.	0.6	2
124	Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa. <i>Blood</i> , 2019, 134, 352-352.	0.6	7
125	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5310-5310.	0.6	3
126	Earlier Steroid Use with Axicabtagene Ciloleucef (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 243-243.	0.6	42

#	ARTICLE	IF	CITATIONS
127	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	0.6	24
128	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two <sc>LYSA</sc> studies. <i>Cancer Medicine</i> , 2018, 7, 539-548.	1.3	10
129	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018, 32, 1799-1803.	3.3	67
130	Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). <i>Digestive and Liver Disease</i> , 2018, 50, 124-131.	0.4	25
131	Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 237-244.	1.0	7
132	Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?. <i>British Journal of Haematology</i> , 2018, 180, 304-308.	1.2	3
133	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. <i>Seminars in Hematology</i> , 2018, 55, 179-181.	1.8	7
134	TP53, XPO1 and ATM Mutations Exclusive Distribution in the Adverse Prognosis Chronic Lymphocytic Leukemia (CLL) Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S218.	0.2	0
135	Definition of a minimal genes set for mature lymphoid blood diseases. <i>Hematologie</i> , 2018, 24, 27-59.	0.0	4
136	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	1.2	41
137	Curing diffuse large B-cell lymphomas in elderly patients. <i>European Journal of Internal Medicine</i> , 2018, 58, 14-21.	1.0	10
138	High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S217-S218.	0.2	0
139	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. <i>Nature Genetics</i> , 2018, 50, 1650-1657.	9.4	151
140	Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. <i>Leukemia</i> , 2018, 32, 2590-2603.	3.3	59
141	Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2287-2293.	1.0	27
142	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	0.6	25
143	Optimizing initial therapy in DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 199-208.	0.7	15
144	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the <sc>EBMT</sc> Lymphoma Working Party and <sc>FIL</sc> & <sc>GITMO</sc>. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19

#	ARTICLE	IF	CITATIONS
145	Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. Japanese Journal of Clinical Oncology, 2018, 48, 736-742.	0.6	3
146	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Blood, 2018, 132, 228-228.	0.6	14
147	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. Blood, 2018, 132, 446-446.	0.6	2
148	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 784-784.	0.6	16
149	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 4196-4196.	0.6	16
150	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922.	0.6	2
151	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. Blood, 2018, 132, 1677-1677.	0.6	2
152	Abstract 5616: Rituximab chemotherapy induces a partial recovery from T-cell exhaustion in follicular lymphoma patients. , 2018, , .		0
153	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy " a Study By the Lysa Group. Blood, 2018, 132, 4099-4099.	0.6	0
154	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. Blood, 2018, 132, 2846-2846.	0.6	0
155	Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study. Blood, 2018, 132, 4199-4199.	0.6	0
156	Hepatitis B Virus Associated B-Cell Non-Hodgkin Lymphoma in Non-Endemic Areas. Blood, 2018, 132, 4228-4228.	0.6	2
157	Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome. Blood, 2018, 132, 1569-1569.	0.6	0
158	Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best Practice and Research in Clinical Haematology, 2017, 30, 109-117.	0.7	42
159	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood, 2017, 129, 2224-2232.	0.6	243
160	Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. Therapeutic Drug Monitoring, 2017, 39, 43-54.	1.0	70
161	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of Oncology, 2017, 28, 2169-2178.	0.6	207
162	Management of aggressive lymphoma in very elderly patients. Hematological Oncology, 2017, 35, 49-53.	0.8	10

#	ARTICLE	IF	CITATIONS
163	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	0.6	21
164	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
165	Targeting of Bâ€cell receptor signalling in Bâ€cell malignancies. <i>Journal of Internal Medicine</i> , 2017, 282, 415-428.	2.7	37
166	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	0.8	22
167	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	13.9	313
168	Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. <i>Annals of Oncology</i> , 2017, 28, 2680-2690.	0.6	14
169	Discovery of Human-Similar Gene Fusions in Canine Cancers. <i>Cancer Research</i> , 2017, 77, 5721-5727.	0.4	22
170	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	0.6	149
171	FDG-PETâ€driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017, 130, 1315-1326.	0.6	87
172	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	3.7	70
173	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017, 52, 216-221.	1.3	102
174	Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. <i>Oncotarget</i> , 2017, 8, 80073-80082.	0.8	12
175	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 371-378.	0.9	24
176	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	0.8	148
177	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
178	HHV-6 reactivation as a cause of fever inâautologous hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2017, 75, 155-159.	1.7	13
179	Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes. , 2017, , .		2
180	Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. <i>Oncotarget</i> , 2017, 8, 16243-16258.	0.8	8

#	ARTICLE	IF	CITATIONS
181	VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. <i>Oncotarget</i> , 2017, 8, 90808-90824.	0.8	3
182	Tailoring treatment for MALT lymphoma patients: where do we stand now?. <i>Oncotarget</i> , 2017, 8, 114422-114423.	0.8	1
183	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. <i>Oncotarget</i> , 2016, 7, 83987-84002.	0.8	20
184	A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 722-730.	1.2	49
185	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
186	Efficacy of ibrutinib in the treatment of B-N-eel syndrome. <i>American Journal of Hematology</i> , 2016, 91, E17-9.	2.0	48
187	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016, 48, 1252-1252.	3.1	11
188	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2016, 34, 1386-1394.	0.8	276
189	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , 2016, 101, 336-345.	1.7	50
190	Optimizing therapy for nodal marginal zone lymphoma. <i>Blood</i> , 2016, 127, 2064-2071.	0.6	59
191	Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. <i>British Journal of Haematology</i> , 2016, 175, 735-737.	1.2	11
192	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016, 101, e407-e410.	1.7	38
193	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
194	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016, 47, 1244-1260.	3.1	60
195	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. <i>Leukemia and Lymphoma</i> , 2016, 57, 2425-2428.	0.6	0
196	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , the, 2016, 3, e196-e204.	2.2	344
197	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 390-397.	0.6	54
198	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. <i>Annals of Oncology</i> , 2016, 27, 1349-1350.	0.6	13

#	ARTICLE	IF	CITATIONS
199	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 365-371.	1.3	43
200	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	1.3	216
201	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2016, 55, 397-405.	1.6	72
202	Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2016, 128, 1213-1213.	0.6	9
203	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , 2016, 128, 145-145.	0.6	38
204	Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group. <i>Blood</i> , 2016, 128, 2987-2987.	0.6	1
205	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016, 128, 471-471.	0.6	12
206	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7518-7518.	0.8	1
207	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	1.1	19
208	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. <i>Blood</i> , 2016, 128, 927-927.	0.6	0
209	Tolerance and Efficacy of L-Asparaginase during Induction of Extra-Nodal Natural Killer (NK/T) Lymphoma, Nasal Type, in Real-Life Experience. <i>Blood</i> , 2016, 128, 5351-5351.	0.6	0
210	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	0.6	53
211	Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. <i>Blood</i> , 2015, 126, 1695-1698.	0.6	126
212	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	0.6	130
213	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	3.8	136
214	Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. <i>Annals of Hematology</i> , 2015, 94, 89-95.	0.8	20
215	PET-driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP. <i>British Journal of Haematology</i> , 2015, 170, 278-281.	1.2	6
216	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lymphoC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203. ^{2.0}		84

#	ARTICLE	IF	CITATIONS
217	Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006. <i>International Journal of Cancer</i> , 2015, 137, 1217-1223.	2.3	15
218	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2863-2869.	0.6	33
219	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015, 2, e160-e165.	2.2	95
220	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
221	Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1240-1245.	0.6	18
222	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1859-1863.	0.8	4
223	Mantle Cell Lymphoma. , 2015, , 233-243.		1
224	Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3090-3095.	0.6	10
225	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF- κ B-dependent induction of HIF-1 α . <i>Leukemia</i> , 2015, 29, 1163-1176.	3.3	55
226	Inhibitors of BCR signalling interrupt the survival signal mediated by the microenvironment in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2015, 136, 2761-2774.	2.3	47
227	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2025-2031.	0.6	6
228	Analytical Performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with Diffuse Large B-Cell Lymphoma Core Needle Biopsy Samples. <i>Blood</i> , 2015, 126, 1481-1481.	0.6	1
229	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 1532-1532.	0.6	5
230	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 338-338.	0.6	19
231	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015, 126, 517-517.	0.6	2
232	Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?. <i>Blood</i> , 2015, 126, 2886-2886.	0.6	1
233	Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 588-588.	0.6	0
234	Treatment of Follicular Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 31-37.	0.3	19

#	ARTICLE	IF	CITATIONS
235	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 1854-1860.	0.6	83
236	Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 390-400.	1.2	53
237	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	0.8	79
238	Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2362-2367.	0.6	14
239	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014, 24, 33-42.	4.3	80
240	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 171-175.	9.4	542
241	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899.	1.2	0
242	Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. <i>British Journal of Haematology</i> , 2014, 166, 306-308.	1.2	12
243	Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2023-2030.	3.3	10
244	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , 2014, 15, 1019-1026.	5.1	246
245	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014, 32, 1338-1346.	0.8	137
246	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	0.8	17
247	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. <i>Cancer Research</i> , 2014, 74, CT231-CT231.	0.4	23
248	Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. <i>Blood</i> , 2014, 124, 146-146.	0.6	19
249	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. <i>Blood</i> , 2014, 124, 1625-1625.	0.6	1
250	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3067-3067.	0.6	15
251	Promising Results of Ibrutinib in Three Patients with Secondary Central Nervous System Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3105-3105.	0.6	1
252	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	0.6	7

#	ARTICLE	IF	CITATIONS
253	A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4458-4458.	0.6	8
254	Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. <i>Blood</i> , 2014, 124, 678-678.	0.6	6
255	Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8503-8503.	0.8	2
256	First Lymphoma Study Association workshops Deauville (France), 10th-12th October 2013 "À part 2". <i>Hematologie</i> , 2014, 20, 68-77.	0.0	0
257	A multicenter study of 66 patients with spinal cord compression at diagnosis of B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8560-8560.	0.8	0
258	Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19541-e19541.	0.8	0
259	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study. <i>Blood</i> , 2014, 124, 1657-1657.	0.6	0
260	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	0.6	2
261	Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en <i>Respiratoire et Hématologique</i> . <i>British Journal of Haematology</i> , 2013, 162, 489-497.	1.2	90
262	Actualités thérapeutiques dans les lymphomes. , 2013, , .		0
263	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. <i>European Journal of Cancer</i> , 2013, 49, 2869-2876.	1.3	114
264	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2920-2926.	0.8	137
265	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 525-533.	5.1	257
266	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). <i>Annals of Oncology</i> , 2013, 24, 1032-1037.	0.6	31
267	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	0.8	198
268	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013, 24, 857-877.	0.6	268
269	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
270	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet</i> , The, 2013, 382, 1094.	6.3	2

#	ARTICLE	IF	CITATIONS
271	Pegylated liposomal doxorubicin: an efficient treatment in patients with <sc>H</sc>odgkin lymphoma relapsing after high dose therapy and stem cell transplation. British Journal of Haematology, 2013, 162, 846-848.	1.2	10
272	At diagnosis, diffuse large <sc>B</sc>â€cell lymphoma patients show impaired rituximabâ€mediated <sc>NK</sc>â€cell cytotoxicity. European Journal of Immunology, 2013, 43, 1383-1388.	1.6	19
273	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Annals of Oncology, 2013, 24, 1344-1351.	0.6	75
274	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Annals of Oncology, 2013, 24, 2612-2618.	0.6	30
275	Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. Journal of Clinical Oncology, 2013, 31, 2912-2919.	0.8	185
276	MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. Blood, 2013, 121, 2165-2166.	0.6	25
277	Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival. PLoS ONE, 2013, 8, e55870.	1.1	108
278	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. Blood, 2013, 122, 764-764.	0.6	8
279	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. Blood, 2013, 122, 3005-3005.	0.6	0
280	Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. Blood, 2013, 122, 2202-2202.	0.6	0
281	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	0.6	0
282	Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. Blood, 2013, 122, 3663-3663.	0.6	0
283	Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases. Blood, 2013, 122, 5308-5308.	0.6	0
284	BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. Modern Pathology, 2012, 25, 805-814.	2.9	5
285	Lenalidomide in Diffuse Large B-Cell Lymphoma. Advances in Hematology, 2012, 2012, 1-8.	0.6	18
286	Human Herpesvirus-6 Cytopathic Inclusions. American Journal of Dermatopathology, 2012, 34, e73-e76.	0.3	11
287	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood, 2012, 119, 5126-5132.	0.6	175
288	Therapyâ€related classical <sc>H</sc>odgkin lymphoma after a primary haematological malignancy: a report on 13 cases. British Journal of Haematology, 2012, 158, 644-648.	1.2	4

#	ARTICLE	IF	CITATIONS
289	Treatment of Older Patients with Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2012, 367, 520-531.	13.9	465
290	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012, 23, 2380-2385.	0.6	48
291	MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012, 119, 4619-4624.	0.6	145
292	Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 151-154.	0.2	16
293	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCLnet). <i>Blood</i> , 2012, 120, 151-151.	0.6	52
294	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. <i>Blood</i> , 2012, 120, 152-152.	0.6	13
295	A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study. <i>Blood</i> , 2012, 120, 1617-1617.	0.6	2
296	Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome. <i>Blood</i> , 2012, 120, 1582-1582.	0.6	0
297	Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03â€“6B GELA Study.. <i>Blood</i> , 2012, 120, 2723-2723.	0.6	1
298	Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients. <i>Blood</i> , 2012, 120, 3921-3921.	0.6	0
299	Splenic marginal zone lymphoma: current knowledge and future directions. <i>Oncology</i> , 2012, 26, 194-202.	0.4	20
300	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 460-468.	5.1	420
301	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1858-1867.	6.3	311
302	Non-MALT marginal zone lymphoma. <i>Current Opinion in Hematology</i> , 2011, 18, 273-279.	1.2	25
303	Alteration of BIRC3 and multiple other NF- κ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011, 118, 4930-4934.	0.6	176
304	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
305	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1135-1143.	1.1	4
306	The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4079-4087.	0.8	248

#	ARTICLE	IF	CITATIONS
307	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 37-43.	0.6	280
308	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. <i>Blood</i> , 2011, 118, 2632-2632.	0.6	5
309	Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). <i>Blood</i> , 2011, 118, 268-268.	0.6	3
310	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. <i>Blood</i> , 2011, 118, 2718-2718.	0.6	2
311	An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,. <i>Blood</i> , 2011, 118, 3715-3715.	0.6	6
312	Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL). <i>Blood</i> , 2011, 118, 2673-2673.	0.6	0
313	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. <i>Blood</i> , 2011, 118, 502-502.	0.6	1
314	MALT lymphomas: pathogenesis can drive treatment. <i>Oncology</i> , 2011, 25, 1134-42, 1147.	0.4	40
315	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104.	0.6	122
316	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010, 116, 1479-1488.	0.6	174
317	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> , 2010, 116, 2040-2045.	0.6	1,193
318	Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 262-269.	0.2	52
319	Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. <i>Blood</i> , 2010, 116, 5119-5125.	0.6	123
320	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	27
321	Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL). <i>Blood</i> , 2010, 116, 2860-2860.	0.6	3
322	Second-line treatment paradigms for diffuse large B-cell lymphomas. <i>Current Oncology Reports</i> , 2009, 11, 386-393.	1.8	27
323	Gain of function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 920-926.	1.7	144
324	Phase I/II Study of IPH1101, a T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.. <i>Blood</i> , 2009, 114, 1649-1649.	0.6	6

#	ARTICLE	IF	CITATIONS
325	Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 884-884.	0.6	41
326	Non-gastric extranodal marginal zone lymphomas: a challenge in routine practice. Leukemia and Lymphoma, 2008, 49, 2229-2230.	0.6	4
327	Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.. Blood, 2008, 112, 1780-1780.	0.6	3
328	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Étude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 2007, 25, 787-792.	0.8	239
329	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 2005, 104, 1434-1441.	2.0	35
330	Clinical Presentation and Management of Marginal Zone Lymphomas. Hematology American Society of Hematology Education Program, 2005, 2005, 307-313.	0.9	102
331	Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity?. Clinical Lymphoma and Myeloma, 2005, 5, 220-224.	2.1	50
332	Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica, 2005, 90, 470-8.	1.7	67
333	Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncology, The, 2003, 4, 95-103.	5.1	161
334	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. Leukemia and Lymphoma, 2003, 44, 257-262.	0.6	29
335	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.	0.6	391
336	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. Clinical Lymphoma and Myeloma, 2002, 3, 41-47.	2.1	148
337	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood, 2000, 95, 802-806.	0.6	484
338	Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood, 2000, 95, 1950-1956.	0.6	279